TWINBEECH CAPITAL LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
TWINBEECH CAPITAL LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$4,839,109
-3.2%
92,899
-13.5%
0.09%
-29.5%
Q3 2022$4,997,000
+562.7%
107,391
+771.9%
0.13%
+300.0%
Q1 2022$754,000
-6.7%
12,317
-37.8%
0.03%
-66.3%
Q2 2021$808,00019,7940.10%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders